Do analysts rate NTRB or ADIL?

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 134.61%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Do analysts rate RYM or ADIL?

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 134.61%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adial Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Adial Pharmaceuticals (ADIL) Competitors

$6.66 +0.34 (+5.38%)

As of 09/3/2026 04:00 PM Eastern

Compare

ADIL vs. HRTX, CLNN, SCYX, NTRB, and RYM

Should you buy Adial Pharmaceuticals stock or one of its competitors? Adial Pharmaceuticals's main competitors and comparable companies include Heron Therapeutics (HRTX), Clene (CLNN), SCYNEXIS (SCYX), Nutriband (NTRB), and RYTHM (RYM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Adial Pharmaceuticals compare to Heron Therapeutics?

Adial Pharmaceuticals (NASDAQ:ADIL) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Adial Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

Adial Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -22.52%. Adial Pharmaceuticals' return on equity of -203.87% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

In the previous week, Heron Therapeutics had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for Adial Pharmaceuticals. Heron Therapeutics' average media sentiment score of 1.36 beat Adial Pharmaceuticals' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
Heron Therapeutics	Positive

Adial Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 134.61%. Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 506.06%. Given Heron Therapeutics' higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Adial Pharmaceuticals has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Heron Therapeutics	$154.90M	0.40	-$20.19M	-$0.19	N/A

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Heron Therapeutics beats Adial Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Clene?

Adial Pharmaceuticals (NASDAQ:ADIL) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Adial Pharmaceuticals presently has a consensus target price of $15.63, indicating a potential upside of 134.61%. Clene has a consensus target price of $33.25, indicating a potential upside of 733.33%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adial Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Adial Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
Clene	-20,063.96%	N/A	-137.04%

In the previous week, Clene had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 1 mentions for Clene and 0 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.00 equaled Clene'saverage media sentiment score.

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
Clene	Neutral

Adial Pharmaceuticals has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
Clene	$200K	256.36	-$26.17M	-$3.50	N/A

Summary

Clene beats Adial Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to SCYNEXIS?

Adial Pharmaceuticals (NASDAQ:ADIL) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, SCYNEXIS had 3 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for Adial Pharmaceuticals. SCYNEXIS's average media sentiment score of 0.25 beat Adial Pharmaceuticals' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Adial Pharmaceuticals	Neutral
SCYNEXIS	Neutral

Adial Pharmaceuticals has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-203.87%	-512.41%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Adial Pharmaceuticals has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A
SCYNEXIS	$20.60M	2.58	-$8.61M	-$2.09	N/A

Adial Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Adial Pharmaceuticals currently has a consensus price target of $15.63, indicating a potential upside of 134.61%. SCYNEXIS has a consensus price target of $33.00, indicating a potential upside of 517.98%. Given SCYNEXIS's higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Adial Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 8.0% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

SCYNEXIS beats Adial Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to Nutriband?

Nutriband (NASDAQ:NTRB) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Nutriband has a beta of 2.03, suggesting that its stock price is 103% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Adial Pharmaceuticals has lower revenue, but higher earnings than Nutriband. Nutriband is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	33.56	-$8.23M	-$2.58	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 52.2% of Nutriband shares are owned by company insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Nutriband's average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Nutriband	Neutral
Adial Pharmaceuticals	Neutral

Adial Pharmaceuticals has a net margin of 0.00% compared to Nutriband's net margin of -448.25%. Nutriband's return on equity of -112.64% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-448.25%	-112.64%	-97.86%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 134.61%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Adial Pharmaceuticals is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Nutriband beats Adial Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Adial Pharmaceuticals compare to RYTHM?

RYTHM (NASDAQ:RYM) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 8.0% of Adial Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Adial Pharmaceuticals has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	3.16	-$33.26M	-$10.53	N/A
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$14.73	N/A

Adial Pharmaceuticals has a consensus target price of $15.63, suggesting a potential upside of 134.61%. Given Adial Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Adial Pharmaceuticals is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adial Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, RYTHM's average media sentiment score of 0.00 equaled Adial Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
Adial Pharmaceuticals	Neutral

RYTHM has a beta of 9.44, suggesting that its share price is 844% more volatile than the broader market. Comparatively, Adial Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Adial Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Adial Pharmaceuticals	N/A	-203.87%	-512.41%

Summary

Adial Pharmaceuticals beats RYTHM on 8 of the 13 factors compared between the two stocks.

Get Adial Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADIL vs. The Competition

Export

Metric	Adial Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.60M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.45	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	-0.46	12.33	12.89	6.14
Net Income	-$7.98M	$2.82B	$3.47B	$349.01M
7 Day Performance	18.93%	2.59%	0.60%	-0.27%
1 Month Performance	75.26%	6.95%	5.73%	0.68%
1 Year Performance	-23.89%	9.45%	25.35%	14.84%

Adial Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADIL Adial Pharmaceuticals	2.7775 of 5 stars	$6.66 +5.4%	$15.63 +134.6%	-28.8%	$16.60M	N/A	N/A	20
HRTX Heron Therapeutics	2.1853 of 5 stars	$0.32 +2.5%	$2.00 +531.5%	-75.2%	$60.13M	$154.90M	N/A	300	Positive News Gap Up
CLNN Clene	1.865 of 5 stars	$4.34 -0.7%	$33.25 +666.1%	-28.6%	$55.77M	$197K	N/A	100
SCYX SCYNEXIS	3.3087 of 5 stars	$5.25 +0.6%	$33.00 +528.6%	-20.5%	$52.24M	$20.60M	N/A	60	Gap Down
NTRB Nutriband	0.1125 of 5 stars	$4.25 +11.3%	N/A	-11.3%	$51.66M	$1.80M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADIL) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. HRTX, CLNN, SCYX, NTRB, and RYM

How does Adial Pharmaceuticals compare to Heron Therapeutics?

Summary

How does Adial Pharmaceuticals compare to Clene?

Summary

How does Adial Pharmaceuticals compare to SCYNEXIS?

Summary

How does Adial Pharmaceuticals compare to Nutriband?

Summary

How does Adial Pharmaceuticals compare to RYTHM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adial Pharmaceuticals (ADIL) Competitors

ADIL vs. HRTX, CLNN, SCYX, NTRB, and RYM

How does Adial Pharmaceuticals compare to Heron Therapeutics?

Which has more volatility & risk, ADIL or HRTX?

Is ADIL or HRTX more profitable?

Does the media refer more to ADIL or HRTX?

Do analysts prefer ADIL or HRTX?

Which has preferable valuation & earnings, ADIL or HRTX?

Do institutionals and insiders believe in ADIL or HRTX?

Summary

How does Adial Pharmaceuticals compare to Clene?

Do analysts recommend ADIL or CLNN?

Do insiders and institutionals believe in ADIL or CLNN?

Which has more volatility and risk, ADIL or CLNN?

Is ADIL or CLNN more profitable?

Does the media refer more to ADIL or CLNN?

Which has better earnings and valuation, ADIL or CLNN?

Summary

How does Adial Pharmaceuticals compare to SCYNEXIS?

Does the media refer more to ADIL or SCYX?

Is ADIL or SCYX more profitable?

Which has higher valuation and earnings, ADIL or SCYX?

Which has more volatility & risk, ADIL or SCYX?

Do analysts recommend ADIL or SCYX?

Do institutionals & insiders believe in ADIL or SCYX?

Summary

How does Adial Pharmaceuticals compare to Nutriband?

Which has more risk and volatility, NTRB or ADIL?

Which has higher earnings and valuation, NTRB or ADIL?

Do institutionals & insiders hold more shares of NTRB or ADIL?

Does the media prefer NTRB or ADIL?

Is NTRB or ADIL more profitable?

Do analysts rate NTRB or ADIL?

Summary

How does Adial Pharmaceuticals compare to RYTHM?

Do insiders and institutionals hold more shares of RYM or ADIL?

Which has stronger valuation & earnings, RYM or ADIL?

Do analysts rate RYM or ADIL?

Does the media favor RYM or ADIL?

Which has more volatility & risk, RYM or ADIL?

Is RYM or ADIL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADIL vs. The Competition

Adial Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools